The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nimotuzumab combined with paclitaxel and cisplatin as first-line treatment for metastatic esophageal squamous cell carcinoma: A prospective, multicenter, double-blind, randomized controlled clinical study.
 
Zhihao Lu
No Relationships to Disclose
 
Miaozhen Qiu
No Relationships to Disclose
 
Bin Hu
No Relationships to Disclose
 
Lianke Liu
No Relationships to Disclose
 
Tianshu Liu
No Relationships to Disclose
 
Lei Chen
No Relationships to Disclose
 
Li Enxiao
No Relationships to Disclose
 
Tao Sun
No Relationships to Disclose
 
Xiaohong Wu
No Relationships to Disclose
 
Yiping Zhang
No Relationships to Disclose
 
Dai Guanghai
No Relationships to Disclose
 
Chunjiao Wu
No Relationships to Disclose
 
Xiaoyan Lin
No Relationships to Disclose
 
Xiaobing Chen
No Relationships to Disclose
 
Ningju Wang
No Relationships to Disclose
 
Hongming Pan
No Relationships to Disclose
 
Yu-Xian Bai
No Relationships to Disclose
 
Xiuli Yang
No Relationships to Disclose
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)
 
Rui- Xu
No Relationships to Disclose